Synairgen Share Discussion Threads

[deejay007] 09/11/2009 08:58

tipped a day too late ! :(

[induna123] 09/11/2009 08:45

Had a look on iii. Apparently it's been tipped in RHPS this weekend.

[neillp] 13/10/2009 14:09

There was a feature article in the September 2009 edition of Aimzine ( inc interview with the MD Richard Marsden. Free to view but registration required.

[investinggarden] 04/9/2009 11:15

Synairgen braced for 'pivotal' studies

[the_doctor] 29/5/2009 11:33

Taking a look.....

[cagr] 28/6/2007 20:50

An interesting prospect Chopsy.

Backed by some very able and highly regarded fund managers at Lansdowne Partners, the technology has truely blockbusting potential.

I believe the company are in active talks with Roche regarding a JV for the further testing of SNG's anti-asthma drug. Still in phase I which is very early stage, the risks are extremely high but the potential pay off should the drug go through to commercialisation give this 10-20 bagger potential.

Todays director buy, not small either, looks very promising...

[chopsy] 28/6/2007 18:39

cagr: what do think about this company's prospects?

[cagr] 28/6/2007 14:47

Synairgen plc
28 June 2007


Synairgen plc ('Synairgen' or the 'Company')

Directors' Shareholdings


The Company was informed on 27 June 2007 that Simon Shaw, Non-executive Chairman
of Synairgen, acquired 40,000 ordinary shares of 1p each in the Company ('
Ordinary Shares') at a price of 61 pence per share on 26 June 2007. As a
consequence of this transaction, his holding in the Company equates to 55,400
Ordinary Shares, which represents approximately 0.3 per cent. of the issued
ordinary share capital of the Company. Taking account of his 700,000 Founder
Options (exercisable at nominal value) his total interest represents
approximately 3.5 per cent. of the issued share capital.

The Company was informed on 28 June 2007 that John Ward, Finance Director of
Synairgen, acquired 15,000 Ordinary Shares in the Company at a price of 60.75
pence per share on 28 June 2007. As a consequence of this transaction, his
holding in the Company equates to 22,692 Ordinary Shares, which represents
approximately 0.1 per cent. of the issued ordinary share capital of the Company.



This information is provided by RNS
The company news service from the London Stock Exchange

[cagr] 30/5/2007 20:25

Synairgen is a drug discovery company specialising in respiratory diseases with a focus on asthma and chronic obstructive pulmonary disease (COPD). These diseases are rapidly growing causes of morbidity and mortality worldwide and represent an increasing and largely unmet medical need.

At Synairgen, we focus on the discovery of new drugs which address the underlying causes rather than the symptoms of asthma and COPD. We aim to do this both in-house and via collaborations with industry partners, using our advanced in vitro cell models of human disease. The founding technology stems from at least twenty years of development in the laboratories at the University of Southampton led by Professors Stephen Holgate, Donna Davies and Ratko Djukanovic.